Respiratory Syncytial Virus Infection Clinical Trial
Official title:
Observational Study of the Effectiveness of Synagis Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus Infection
Published data by the Organización panamericana de la Salud shows that Peru's mortality rate from acute respiratory infections (ARI) in infants less than one year of life is second only to Haiti (14,150/100,000). Government data reports shows a marked increase of RSV infections in Peru. "Instituto Nacional de Salud" (Peru's National Institute of Health) reports between January 1st to February 26th 2006, 62% of their positive samples corresponded to RSV. Epidemiological data from Lima-Peru, demonstrates that there is no specific season for RSV infection although some data suggest an increase in RSV activity during cold months (May to September; INS data). Clinical studies show that giving five doses of Synagis (palivizumab) resulted in serum concentrations > 30 ug/mL for >20 weeks. The aim of this post-marketing observational study is to determine the RSV hospitalization rate in high-risk infants who received Synagis (palivizumab) through the Social Security Hospitals in the context of routine clinical practice.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02016690 -
Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immuno Compromised Children With Synagis
|
N/A | |
| Completed |
NCT04491877 -
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
|
Phase 2 | |
| Completed |
NCT05987072 -
A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
|
Phase 1 | |
| Completed |
NCT01006629 -
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
|
Phase 2/Phase 3 | |
| Completed |
NCT00593918 -
Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
|
N/A | |
| Recruiting |
NCT06134648 -
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
|
Phase 1/Phase 2 | |
| Completed |
NCT03473002 -
A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02135614 -
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2 | |
| Completed |
NCT01909843 -
ALX-0171 Safety Study in Adults With Hyperresponsive Airways
|
Phase 1 | |
| Recruiting |
NCT06206720 -
A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
|
Phase 2 | |
| Completed |
NCT02254421 -
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
|
Phase 2 | |
| Recruiting |
NCT06237296 -
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
|
Phase 1 | |
| Completed |
NCT01537198 -
Surveillance of Synagis in Korean Pediatric Patients
|
N/A | |
| Recruiting |
NCT05687279 -
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
|
Phase 1/Phase 2 | |
| Completed |
NCT01297504 -
A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America
|
N/A | |
| Recruiting |
NCT06079320 -
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2/Phase 3 | |
| Completed |
NCT02309320 -
A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06194318 -
First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01466062 -
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
|
Phase 3 | |
| Active, not recruiting |
NCT04767373 -
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
|
Phase 2/Phase 3 |